Most Recent
Settlement talks in three class actions on behalf of women injured by allegedly defective pelvic mesh products have progressed “substantially”, a court has heard.
The High Court has agreed to weigh in on whether property data analytics firm CoreLogic infringed a real estate photographer's copyright by uploading images from realestate.com.au to its platform.
An additional 1,200 women who were implanted with defective pelvic mesh devices will be eligible for compensation after Johnson & Johnson unit Ethicon agreed that findings in an earlier class action which it unsuccessfully fought all the way to the High Court should apply to a follow-on class action.
The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.
The High Court has found that Novartis unit Sandoz infringed Danish drug company Lundbeck's patent for its blockbuster antidepressant Lexapro, but has overturned a ruling that found the generic drug maker owes $26.3 million in damages.
Buy now, pay later giant Zip Co cannot rely on its infringing use of the 'Zip' trade mark to defend a lawsuit by the mark's owner Firstmac, the mortgage provider's barrister told a judge on the first day of trial in the high-stakes intellectual property dispute.
The maker of Mother brand energy drinks has filed an appeal challenging a judge's decision to remove two of its registered 'Mother' trade marks for non-use.
Settlement talks in a class action brought by Shine Lawyers against Astora Women's Health on behalf of women injured by allegedly defective pelvic mesh products are "well advanced", while mediation in two similar actions is ongoing, a court has heard.
The ACCC got what it wanted when IVF providers Virtus Health and Healius terminated a proposed $45 million merger, but it wasn't a win, a judge has said in mostly denying the regulator's bid to recover the costs of its court challenge to the deal.
Bristol-Myers Squibb unit Celgene has dropped a lawsuit accusing Indian generics company Dr Reddy's Laboraties of threatening to infringe its patent for Revlimid with the planned launch of a generic version of the blockbuster cancer drug in Australia.